Skip to contentD
DNA X, Inc.
D
SONMDNA X, Inc. Q4 2022 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$24.12M$24.12Mderived+51.4% vs Q4 2021 Net Income-$1.04M-$1.04MderivedN/M vs Q4 2021 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
DNA X, Inc. · CIK 1178697 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$3,932,000N/M Operating Incomederived-$1,059,000N/M Operating Cash Flowderived-$2,221,000N/M Free Cash Flowderived-$2,223,000N/M Margins · derivedGross margin16.3%+19.4 pt vs Q4 2021
Operating margin-4.4%+69.3 pt vs Q4 2021
Net margin-4.3%+69.3 pt vs Q4 2021
ended Dec 31, 2022 · filed Mar 20, 2023 · 79 d after period end